title: Cardiovascular risk and mineral bone disorder in patients with chronic kidney disease.
abstract: The term chronic kidney disease-mineral bone disorder has been coined recently to highlight that the disturbed mineral and bone metabolism is a major contributor to vascular calcification and finally cardiovascular disease. This syndrome is characterized by clinical, biochemical and/or histological findings, i.e. i) biochemical alterations in the homeostasis of calcium, phosphate and their key player parathyroid hormone (PTH), Fibroblast growth factor-23 (FGF-23), klotho and vitamin-D, ii) the occurrence of vascular and/or soft tissue calcification, and iii) an abnormal bone structure and/or turnover. Apart from the combined and synergistic action of "traditional" and uremia-related risk factors, promoters and inhibitors of calcification have to be considered as well. This review will focus on the disturbed mineral metabolism as the triggering force behind distortion of vascular integrity and cardiovascular malfunction in CKD patients.
authors.affiliation: Department of Pediatrics, University Children's Hospital Rostock, Germany.
authors.forename: Hagen
authors.initials: H
authors.lastname: Staude
authors.forename: Susann
authors.initials: S
authors.lastname: Jeske
authors.forename: Karin
authors.initials: K
authors.lastname: Schmitz
authors.forename: Gert
authors.initials: G
authors.lastname: Warncke
authors.forename: Dagmar-Christiane
authors.initials: DC
authors.lastname: Fischer
mesh_terms: D000818:Animals; D001847:Bone Diseases / Q000453:epidemiology / Q000209:etiology / Q000378:metabolism*; D002113:Calcification, Physiologic / Q000502:physiology*; D002114:Calcinosis / Q000453:epidemiology / Q000209:etiology / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology / Q000378:metabolism*; D000089703:Fibroblast Growth Factor-23; D006801:Humans; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000453:epidemiology / Q000378:metabolism*; D012307:Risk Factors